The "Drug Overview: Invega Sustenna/Invega Trinza" report has been added to ResearchAndMarkets.com's offering. Invega Sustenna and Invega Trinza (paliperidone palmitate; Johnson & Johnson) are ...

TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...

After incurring a loss in New Jersey federal court in 2021, Teva and Viatris have successfully resurrected challenges to the last remaining U.S. patent on a lucrative Johnson & Johnson schizophrenia ...

Paliperidone (as palmitate) 273mg, 410mg, 546mg, 819mg; ext-rel susp for IM inj. Schizophrenia after adequately treated with Invega Sustenna (1-month paliperidone palmitate ext-rel inj susp) for at ...

Johnson & JohnsonJNJ suffered a setback when the FDA issued a complete response letter (CRL) in response to the company's supplemental new drug application (sNDA) for the once-monthly long-acting ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. INVEGA SUSTENNA contains the active ingredient paliperidone palmitate.

Schizophrenia is a mental health disorder that causes changes to the way a person thinks, acts, and behaves. People with schizophrenia may have hallucinations, delusions, disorganized behavior, and ...

Johnson & Johnson JNJ announced that the FDA has approved another long-acting formulation of its antipsychotic drug, paliperidone palmitate, Invega Hafyera, for treating schizophrenia in adults.

Johnson & Johnson wrapped a Phase III study of a 3-month formulation of Invega Sustenna early after an independent monitoring group called it on positive efficacy ...